Venomics AI, a Bengaluru-based startup founded by Indian Institute of Science (IISc) associate professor Kartik Sunagar and Vinay Prabhu that uses artificial intelligence to hunt for drug candidates in animal venom, has raised a $2.7 million pre-seed round from three investors, including Speciale Invest and South Park Commons, according to coverage dated November 5.
Entrepreneur India described the money as the company's first institutional funding. Inc42 and VCCircle put the rupee equivalent at ₹25.5 crore. Venomics did not disclose a valuation.
A Bet on an Old Idea
Medicine has been borrowing from venom for decades, and Venomics is wagering that machine learning can search that chemistry faster than traditional methods. CXOtoday, in its coverage of the announcement, pointed to captopril, a drug inspired by snake venom, as a precedent. FDA documents describe ziconotide (sold as Prialt) as a synthetic version of a peptide from the cone snail Conus magus, and exenatide (Byetta) as a synthetic GLP-1 receptor agonist first identified in the Gila monster, Heloderma suspectum.
What the Company Is, and Is Not
The startup says it is building a discovery platform rather than a marketed medicine. Its website invites inquiries about partnerships, licensing and scientific collaboration, and lists research focus areas that reach into agricultural and vector-control uses. Those are areas of interest, not validated drug programmes.
The company has published figures about its dataset, but they are self-reported. Its site does not say how entries were deduplicated or experimentally validated, which matters in a field where data quality can make or break a model.
Sunil Cavale, a partner at Speciale Invest, laid out the firm's thesis in a post titled "Evolution's Unread Pharmacy: Why We Backed Venomics AI." The post says Speciale is investing from its $70 million Fund III, a figure the investor itself reported. Business Standard, ETEntrepreneur and CIOL carried statements from founders and investors; their wording was not available for this article, so none is reproduced here.
The Founders
Kartik Sunagar, an associate professor at IISc (many outlets call him "professor"), co-founded the company with Vinay Prabhu. The company's chronology says the two reunited in India in January 2026 after 15 years apart, and that Venomics was conceived then. Business Standard's funding story also named Purba Sarkar.
According to the company, Prabhu holds a PhD in electrical and computer engineering from Carnegie Mellon and an MSEE from IIT Madras. He also co-founded HAL51.AI with Sanghyun Han, a frugal-science and XR hardware startup behind LemurBox.
Venomics' website lists ten people, or nine if a visiting scientist is excluded. That is a web roster rather than a verified headcount, and several of those listed have IISc affiliations.
Dates That Don't Quite Match
The timeline is untidy. Entrackr, citing a press release, said the company was co-founded in May 2026. ZaubaCorp, a third-party aggregator, lists Venomics AI Private Limited as incorporated on May 15, 2026. Yet the company's own news page dates the $2.7 million pre-seed to April 10, 2026, and search-indexed versions of that page once said roughly $3 million. The live page now says $2.7 million.
Sunagar's October 2026 CV lists ₹25.5 crore for the startup, starting October 1. That does not establish a legal closing date for the round.
Competitors and Open Questions
The research identified UK-based Venomtech as a relevant comparator for its platform and library, though not necessarily an identical business. The reporting reviewed did not name a pharmaceutical customer, a signed licensing deal, revenue or a clinical-trial identifier. Entrepreneur India said no cheque sizes, ownership stakes or board seats were disclosed.
StartupRise's coverage addressed hiring and dataset expansion as next steps, but the company did not publish specific targets in the materials reviewed. For now, Venomics has money, a pedigree and a promising premise. What it has yet to show is a partner, a validated dataset or a drug programme.
